Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vilazodone
Drug ID BADD_D02456
Description Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Indications and Usage Vilazodone is approved for treatment of major depressive disorder.[Label,A38477,A177622]
Marketing Status approved
ATC Code N06AX24
DrugBank ID DB06684
KEGG ID D09698
MeSH ID D000069503
PubChem ID 6918314
TTD Drug ID D0X6BV
NDC Product Code Not Available
UNII S239O2OOV3
Synonyms Vilazodone Hydrochloride | Hydrochloride, Vilazodone | 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) | Vilazodone HCl | HCl, Vilazodone | Viibryd | EMD 68843 | 68843, EMD | EMB-68843 | EMB 68843 | EMB68843 | Vilazodone | 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide
Chemical Information
Molecular Formula C26H27N5O2
CAS Registry Number 163521-12-8
SMILES C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Screaming19.04.02.020; 08.01.03.0990.000703%Not Available
Sedation17.02.04.0050.002108%Not Available
Seizure17.12.03.0010.004440%
Sensory disturbance17.02.07.0060.000703%Not Available
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.003578%Not Available
Sexual dysfunction21.03.02.003; 19.08.05.0020.006676%Not Available
Shock24.06.02.0020.000319%Not Available
Sleep disorder19.02.04.0010.001789%Not Available
Sleep paralysis19.02.02.004; 17.15.02.0050.004281%Not Available
Sleep terror19.02.03.008; 17.15.02.0060.002651%Not Available
Somnolence17.02.04.006; 19.02.05.0030.004440%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000319%Not Available
Suicidal ideation19.12.01.0030.010925%
Suicide attempt19.12.01.0040.002715%
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.0180.001086%Not Available
Tardive dyskinesia17.01.02.0120.001629%Not Available
Therapeutic response decreased08.06.01.0160.001629%Not Available
Therapeutic response unexpected08.06.01.0010.001406%Not Available
Tic17.02.05.024; 19.11.04.0010.001086%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.001565%
Tongue disorder07.14.01.0020.000703%Not Available
Tremor17.01.06.0020.004856%
Tunnel vision17.17.01.013; 06.02.07.0050.000319%Not Available
Urinary retention20.02.02.0110.000479%
Vertigo17.02.12.002; 04.04.01.0030.001629%
Vision blurred17.17.01.010; 06.02.06.0070.002811%
Vomiting07.01.07.0030.007028%
Withdrawal syndrome08.06.02.012; 19.07.06.0230.006676%Not Available
Mental status changes19.07.01.0010.000703%Not Available
Energy increased08.01.03.0170.001246%Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages